Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. develops clinical-stage protein kinase inhibitor therapeutics for cardiopulmonary disease, with IKT-001, an oral prodrug of imatinib mesylate, as its lead program for pulmonary arterial hypertension. Company news centers on the IMPROVE-PAH clinical program, FDA interactions, clinical-development milestones, and PAH biology involving Abelson tyrosine kinase, platelet-derived growth factor receptors and c-KIT.
Recurring updates also cover operating results, development spending, equity compensation under Nasdaq rules, common-stock and warrant financing activity, and leadership or commercial-planning changes tied to the PAH program.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Inhibikase Therapeutics, a clinical-stage pharmaceutical company, provided updates on its Phase 2 '201' program for IkT-148009, aimed at treating Parkinson's disease, after the FDA lifted the clinical hold. The trial is progressing with 35 sites selected, expecting 11 to screen patients by April's end and 30 by Q2 2023. Importantly, state-of-the-art biomarker analyses for alpha-synuclein are now integrated into the trial. The safety and pharmacokinetics of a 200 mg dose have been evaluated in healthy volunteers, supporting its inclusion in the trial. Encouraging data from previous Phase 1b studies indicate potential positive treatment effects, although further confirmation is required. Future updates are planned as patient enrollment continues.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation in the 2023 Planet MicroCap Showcase on April 26, 2023, at the Horseshoe Hotel & Casino in Las Vegas. Dr. Milton Werner, President & CEO, and Joseph Frattaroli, CFO, will present at 1:00 PM PT. The company is focused on developing therapeutics targeting Parkinson's disease and related disorders, highlighting its lead program, IkT-148009, which inhibits Abelson Tyrosine Kinases (c-Abl). Inhibikase's pipeline also includes therapies for gastrointestinal disorders related to Parkinson's and innovative drug delivery technologies. The event offers an opportunity for investors to gain insights into the company’s strategies and advancements in neurodegeneration treatments.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported financial results for 2022, highlighting a net loss of $18.1 million, or $0.72 per share, compared to a loss of $14.8 million in 2021. The company experienced a significant decrease in grant revenue, down to $0.1 million from $3.1 million. On a positive note, the FDA lifted clinical holds on its IkT-148009 programs for Parkinson's disease and Multiple System Atrophy (MSA). The company also successfully raised $10 million in early 2023 for ongoing clinical trials and product development. Cash position was reported at $23.1 million, expected to support operations into Q4 2024.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced it will report its financial results for Q4 and full-year 2022 on March 31, 2023, after U.S. market close. A conference call and webcast will follow on April 3, 2023, at 8:00 a.m. ET to discuss the results and provide a corporate update. Inhibikase develops protein kinase inhibitor therapeutics aimed at modifying Parkinson's disease and related disorders. Their lead program, IkT-148009, targets treatment for Parkinson's within the brain, along with other cognitive and motor disorders linked to Abelson Tyrosine Kinases.